Minocycline Hydrochloride Hyperpigmentation Complicating Treatment of Pyoderma Gangrenosum

Minocycline-associated hyperpigmentation is an uncommon side effect We report the case of a patient with pyoderma gangrenosum successfully treated with oral minocycline but complicated by marked hyperpigmentation in his pyoderma gangrenosum and acne scars. One of the clinical forms of minocycline hyperpigmentation includes dark-blue or black macules in depressed acne scars or other sites of skin inflammation; this pattern seems to be independent of the total cumulative dose and the skin process.     

米诺环素对小鼠T淋巴细胞体外活化和增殖的影响

研究米诺环素(MNC)对刀豆蛋白A(ConA)刺激的小鼠T细胞体外活化和增殖的影响,并对其免疫调节作用进行初步探讨。以ConA刺激小鼠淋巴结来源的淋巴细胞,以不同终浓度的MNC与T细胞共培养,荧光抗体染色结合流式细胞术,检测T细胞早期活化抗原CD69的表达;用羧基荧光素双醋酸盐琥珀酰(CFDA-SE)染色结合流式细胞术,并用ModFit软件分析T细胞增殖相关指数。结果:终浓度为10、25和50μmol/L的MNC显著抑制ConA诱导的T细胞CD69的表达,由ConA组的71.20%±1.08%,分别降低为64.43%±1.39%、53.34%±1.26%和33.65%±1.91%;CFDA-SE染色结果显示,培养48 h和72 h的ConA组T细胞的增殖指数(PI)分别为1.57±0.03和2.06±0.02,各浓度的MNC对ConA刺激的T细胞增殖具有明显的抑制作用,以50μmol/L的MNC抑制作用最明显,48 h和72 h的PI分别为1.01±0.02和1.03±0.01,与相应时间的对照组比较,均有统计学意义(P<0.01)。MNC能有效地抑制小鼠T细胞的体外活化和增殖。具有独立于其抗菌活性的抗炎作用。     

A systems approach to cancer therapy

Conclusion The molecules described herein as antiangiogenic agents and antimetastatic agents represent a wide variety of molecular structures with a wide variety of biological effects and targets. Most often these agents have been generally classified as antiangiogenic or antimetastatic by their effects in an in vitro bio-assay system. The diversity in this group of molecules gives strength to the potential of this approach in therapeutic applications. The biological and biochemical pathways involved in angiogenesis are numerous and redundant. It is likely that there are many angiogenic factors and many pathways of invasion, therefore it is likely that blockade of more than one pathway related to angiogenesis and/or invasion will be necessary to impact on the natural progress of a malignant disease.The vasculature forms the first barrier to penetration of molecules into tumors. Although the antiangiogenic agent treatments administered in this study did not inhibit angiogenesis in these tumors completely, the vasculature present in the treated tumors may be impaired compared to control tumors. Overall, therefore, the best speculation is that the main targets for the antiangiogenic agents are extracellular matrix processes and/or tumor endothelial cells and that inhibition and/or impairment of these non-malignant functions can improve therapeutic responses when used in combination with cytotoxic therapies. The incorporation of antiangiogenic agents and/or antimetastatic agents into therapeutic regimens represents an important challenge. The successful treatment of cancer requires the eradication of all malignant cells and therefore treatment with cytotoxic therapies. The compatibility of antiangiogenic therapy and/or anti-invasion agents with cytotoxic chemotherapeutic agents is not obvious [316].The goal of the addition of any non-cytotoxic potentiator to a therapeutic regimen is to take a good therapy and, without additional toxicity, push it to cure.Cyclophosphamide is a good drug against the Lewis lung carcinoma although no long-term survivors of animals bearing Lewis lung carcinoma are achieved with cyclophosphamide treatment alone. Adding antiangiogenic agents to treatment of this tumor with cyclophosphamide produced a cure rate of 40–50%, meaning that both the primary and metastatic disease has been eradicated in these animals. Cures were achieved only when the antiangiogenic treatments extended from days 4–18 post Lewis lung tumor implantation. The results obtained with the addition of antiangiogenic agents to cytotoxic anticancer therapies in in vivo models of established solid tumors have been very positive and provide direction for future clinical trials including these antiangiogenic agents. Two conclusions may be drawn. First, combinations of antiangiogenic and/or antimetastatic agents evoke a greater effect on tumor response to therapy than does treatment with single agents of these classes. Second, treatment with antiangiogenic agents and/or antimetastatic agents can interact in a positive way with cytotoxic therapies.     

非淋菌性尿道炎合并盆腔感染药物治疗效果对比研究

目的探讨临床上对非淋菌性尿道(宫颈)炎合并盆腔感染有效的治疗方法。方法将妇产科及性病科门诊确诊的非淋菌性尿道(宫颈)炎合并盆腔感染201例病人随机分为2组,治疗组采用头孢曲松纳加阿奇霉素治疗,对照组采用头孢曲松纳加口服美满霉素治疗。结果治疗组治愈率为80.95%,总有效率为97.14%;对照组治愈率为58.33%,总有效率为69.79%。两者的,临床治愈率及有效率有显著性的差异(P<0.005)。结论头孢曲松纳加阿奇霉素静脉给药治疗非淋菌性尿道(宫颈)炎合并盆腔感染取得良好的治疗效果,较头孢曲松纳加美满霉素效果有显著性提高。     

盐酸米诺环素软膏治疗固定修复体引起的牙周炎的临床评价

目的评价牙周袋内局部使用盐酸米诺环素软膏治疗人工冠和固定义齿引起的牙周炎的临床效果。方法选择由人工冠和固定义齿引起的牙周炎患者32例,随机分为实验组和对照组。在龈上洁治和龈下刮治术后,实验组牙周袋注入盐酸米诺环素软膏,对照组牙周袋内只用生理盐水冲洗,每周1次,共4次。分别记录治疗前和治疗后4周、8周时的牙周指数,包括菌斑指数(PLI)、探诊出血(BOP)、牙周袋探诊深度(PD)等指标,并进行统计学分析。结果治疗后第4周、第8周,2组各项指标的测定值与治疗前比较均有明显改善,且实验组各指标的改善程度均明显优于对照组,差异均有统计学意义(P<0.01)。结论牙周袋内局部使用盐酸米诺环素软膏治疗人工冠和固定义齿引起的牙周炎能够获得较好的临床效果。     

盐酸二甲胺四环素治疗牙周炎的临床疗效观察

目的:研究盐酸二甲胺四环素牙科软膏缓释剂治疗牙周炎的临床疗效。方法:治疗组及对照组患者在治疗前进行牙周检查和牙周洁治,治疗组局部使用盐酸二甲胺四环素牙科软膏缓释剂进行治疗,对照组不给药物。对治疗前后的菌斑指数、牙周袋探诊深度、龈沟出血指数、附着丧失水平进行检查和评价。结果:二甲胺四环素牙科软膏局部治疗4周后患者病牙的临床各项指标包括病牙的菌斑指数、牙周袋探诊深度、龈沟出血指数、附着丧失水平等均比治疗前有明显改善,并且药物治疗组的各项指标改善较对照组更为明显,治疗组用药后第4周末的显效率达79.49%,明显高于对照组的显效率(29.16%),具有统计学意义。结论:盐酸二甲胺四环素牙科软膏缓释剂作为牙周炎的辅助治疗,能有效改善牙周炎的临床各项观察指标。     

反相高效液相色谱法测定注射用盐酸米诺环素含量

目的:探讨用反相高效液相色谱法(RP-HPLC法)测定注射用盐酸米诺环素中盐酸米诺环素含量.方法:采用Waters 2690-996高效液相色谱仪,以Nucleodur C18柱(250 mm×4.6 mm,5μm)为色谱柱,流动相为乙腈-水-三氟乙酸(15:85:0.1,V/V),流速为1.4 mL/min,检测波长为350 nm.结果:盐酸米诺环素的浓度在(12.5～800)μg/mL范围内与峰面积线性关系良好(r=0.999 9),平均回收率为103.24%,RSD=0.52%.结论:该方法操作简便、灵敏、快速,适用于盐酸米诺环素的含量测定.     

盐酸米诺环素联合翻瓣术辅助治疗慢性牙周炎疗效的Meta分析

目的 系统评价牙周翻瓣术中使用2%盐酸米诺环素处理根面的疗效,为其治疗慢性牙周炎提供循证医学证据。方法 检索中国期刊全文数据库、维普、万方、中国生物医学文献数据库、PubMed、ScienceDirect和Embase等数据库,检索时限为从建库到2017年7月。由2名评价员独立筛选文献、提取资料并评价纳入研究的偏倚风险后,采用RevMan 5.3对数据进行Meta分析。结果 最终纳入7个随机对照实验,共217例受试者。Meta分析结果显示,与单纯翻瓣术（FO）组比较,盐酸米诺环素联合翻瓣术（FM）组患者随访3个月时的探诊深度减少[MD=-0.55,95%CI（-0.84,-0.26）,P=0.000 2],菌斑指数降低[MD=-0.08,95%CI（-0.15,-0.01）,P=0.03],随访6个月时探诊深度减少[MD=-0.62,95%CI（-1.04,-0.21）,P=0.003]方面更加明显,组间比较差异有统计学意义（P<0.05）。FM组患者随访3个月时在临床附着丧失获得[MD=-0.21,95%CI（-0.47,0.04）,P=0.10]方面改变的差异无统计学意义（P>0.05）。结论 在翻瓣下机械清创治疗慢性牙周炎中,使用2%盐酸米诺环素处理根面减少探诊深度和炎症控制方面有明显的效果。